ArticleJournal of molecular histology2025
MiR-1293 modulates PPARGC1A to promote proliferation and metastasis of oral carcinoma cells.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to assess the influence of microRNA-1293 (miR-1293) on the proliferation and metastasis of oral carcinoma cells through modulating peroxisome proliferator-activated receptor γ coactivator 1α (PPARGC1A). Carcinoma and para-carcinoma control tissues were sampled from 60 patients with oral carcinoma to measure the expression of miR-1293 and analyze its associations with clinicopathological characteristics. Then qRT-PCR was performed for detecting miR-1293 and PPARGC1A mRNA expressions in oral carcinoma tissues and cells, and Western blotting was conducted to determine PPARGC1A protein expression. The luciferase activity of PPARGC1A-WT significantly dropped, PPARGC1A mRNA and protein expressions reduced, while proliferation, migration, invasion and viability were enhanced in the miR-1293 mimic group compared to the NC mimic group. The miR-1293 mimic + oePPARGC1A group had significantly weaker cell viability and smaller numbers of proliferative, migrating and invasive cells than those of the miR-1293 mimic + oeNC group. The anti-miR-1293 group, in comparison to the anti-NC group, had slower tumor growth in mice, increased mRNA and protein expressions of PPARGC1A in tumor tissues, as well as reduced tumor volume and weight, expression of miR-1293 and degree of tumor malignancy. MiR-1293 facilitates oral carcinoma cell proliferation and metastasis by suppressing the expression of PPARGC1A.
Indexed as
Identifiers
40471458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.